menu
    • menu
    [{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ JSR","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ JSR"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"VE303","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ BARDA"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Pfizer"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"affiliates of Magnetar Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Series D Financing","leadProduct":"VE303","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ affiliates of Magnetar Capital","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ affiliates of Magnetar Capital"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VE303","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VE303","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VE303","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"AXA IM Alts","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"VE303","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ AXA IM Alts","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ AXA IM Alts"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VE303","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Vedanta Biosciences \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ Vedanta Biosciences"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"VE303","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Vedanta Biosciences

    Menu

    Vedanta Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vedanta Biosciences Enrolls First Patient in Phase 3 RESTORATiVE303 Study of VE303

                            Details : VE303 is a potential first-in-class live biotherapeutic product candidate consisting of a defined bacterial consortium designed for the prevention of recurrent Clostridioides difficile infection.

                            Brand Name : VE303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 21, 2024

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE202,Vancomycin Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : PureTech Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 f...

                            Details : VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.

                            Brand Name : VE202

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 04, 2023

                            Lead Product(s) : VE202,Vancomycin Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : PureTech Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease W...

                            Details : VE303 is a defined bacterial consortium therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection (rCDI). It was granted orphan drug designation and fast track designation.

                            Brand Name : VE303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 08, 2023

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : AXA IM Alts

                            Deal Size : $106.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Ther...

                            Details : The financing will be used to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activitie...

                            Brand Name : VE303

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 25, 2023

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : AXA IM Alts

                            Deal Size : $106.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : PureTech Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Ther...

                            Details : VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection.

                            Brand Name : VE303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 28, 2022

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : PureTech Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022...

                            Details : Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence.

                            Brand Name : VE303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 24, 2022

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : PureTech Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host ...

                            Details : Vedanta reported positive topline results from Phase 2 CONSORTIUM trial, in which VE303 was associated with a 31.7% absolute risk reduction in rate of recurrence when compared with placebo, representing a greater than 80% reduction in odds of a CDI recur...

                            Brand Name : VE303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 13, 2022

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : PureTech Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : affiliates of Magnetar Capital

                            Deal Size : $68.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

                            Details : Proceeds expected to be used primarily to support a Phase 3 trial of Vedanta’s lead candidate VE303 in Clostridioides difficile infection (CDI) and a Phase 2 trial of VE202 in inflammatory bowel disease (IBD).

                            Brand Name : VE303

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 21, 2021

                            Lead Product(s) : VE303

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : affiliates of Magnetar Capital

                            Deal Size : $68.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE202

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vedanta Biosciences Presents New Data from Phase 1 Study of VE202 at the International Human Microbiome Consor...

                            Details : Results further support the benign safety profile of VE202 and identify an optimal dosing regimen. Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021.

                            Brand Name : VE202

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 29, 2021

                            Lead Product(s) : VE202

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vedanta Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VE202

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Pfizer Inc

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.

                            Details : Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.

                            Brand Name : VE202

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 12, 2021

                            Lead Product(s) : VE202

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Pfizer Inc

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth